Tabak, FehmiYörük, GülşenKöksal, İftiharErdem, HazalYıldız, Dilekİnce, NevinYamazhan, TansuSume, SerkanBatırel, AyşeGünal, ÖzgürYıldız, İlknur EsenSırmatel, FatmaKoç, Meliha MerihÇeken, SabahatBozkurt, İlkayGörenek, LeventŞener, AlperKöse, ŞükranTürker, Kamuranİnan, DilaraKarabay, OğuzGüner, Rahmet2022-09-202022-09-202021Tabak, F., Yörük, G., Köksal, İ., Erdem, H., Yıldız, D., İnce, N.,...Güner, R. (n.d.). Switching to tenofovir alafenamide in hbv: nationwide real life data of efficacy and safety from Turkey. https://www.webofscience.com/wos/woscc/full-record/WOS:0007071880022200270-91391527-3350https://hdl.handle.net/20.500.12428/3731Tenofovir alafenamide (TAF) is a new prodrug of tenofovir used for the treatment of HIV-1 and HBV infections. It provides more efficient intracellular tenofovir concentrations at a relatively lower dose than provided by tenofovir disoproxil fumarate (TDF). TAF is expected to have efficacy similar to that of TDF with improved safety profile.eninfo:eu-repo/semantics/closedAccessTenofovir alafenamide (TAF)ProdrugHIV-1HBV infectionsConference Object74497A498AQ1WOS:000707188002220